Kinda Shukri
Hamad Medical Corporation(QA)
Publications by Year
Research Areas
COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research, Long-Term Effects of COVID-19, Phytochemicals and Antioxidant Activities, Aortic Disease and Treatment Approaches
Most-Cited Works
- → Tocilizumab for the treatment of severe coronavirus disease 2019(2020)268 cited
- Lowering blood glucose effect of Azadirachta excelsa leaves extract in alloxan induced diabetic rats(2013)
- → Aberrant origin of bilateral vertebral arteries associated with bovine aortic arch(2022)2 cited
- → Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study(2022)
- → 508. Title Favipiravir for the Treatment of Coronavirus Disease 2019; A Propensity Score Matched Cohort Study(2021)
- → Favipiravir for the Treatment of Coronavirus Disease 2019; a propensity score-matched cohort study(2021)